MENU
+Compare
ALLK
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$0.32
Change
+$0.10 (+45.45%)
Capitalization
19.57M

ALLK Allakos Forecast, Technical & Fundamental Analysis

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases... Show more

ALLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ALLK with price predictions
Apr 01, 2025

ALLK in upward trend: price expected to rise as it breaks its lower Bollinger Band on April 01, 2025

ALLK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where ALLK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLK advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLK as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALLK entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.248) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (251.391).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALLK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ALLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALLK is expected to report earnings to fall ∞% to -28 cents per share on May 07

Allakos ALLK Stock Earnings Reports
Q1'25
Est.
$-0.29
Q4'24
Beat
by $0.19
Q3'24
Beat
by $0.04
Q2'24
Beat
by $0.03
Q1'24
Missed
by $0.37
The last earnings report on March 12 showed earnings per share of 0 cents, beating the estimate of -18 cents. With 10.91M shares outstanding, the current market capitalization sits at 19.57M.
A.I. Advisor
published General Information

General Information

a provider of antibody therapeutics for allergic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
825 Industrial Road
Phone
+1 650 597-5002
Employees
131
Web
https://www.allakos.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRGP203.072.60
+1.30%
Targa Resources Corp
CHEK0.800.01
+1.04%
Check-Cap Ltd
CAMT59.140.51
+0.87%
Camtek Ltd
CRVS3.17-0.01
-0.31%
Corvus Pharmaceuticals
ELVN18.88-0.80
-4.07%
Enliven Therapeutics

ALLK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLK has been loosely correlated with VERU. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLK jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLK
1D Price
Change %
ALLK100%
-4.66%
VERU - ALLK
49%
Loosely correlated
+30.54%
AXON - ALLK
38%
Loosely correlated
+2.90%
IMCR - ALLK
33%
Loosely correlated
-3.51%
AMRN - ALLK
32%
Poorly correlated
-1.36%
GANX - ALLK
31%
Poorly correlated
-5.24%
More